Lipocine
LPCN
46 hedge funds and large institutions have $4.85M invested in Lipocine in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 10 reducing their positions, and 7 closing their positions.
3,000% more call options, than puts
Call options by funds: $496K | Put options by funds: $16K
0% more funds holding
Funds holding: 46 → 46 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
0.07% less ownership
Funds ownership: 0.79% → 0.72% (-0.07%)
49% less capital invested
Capital invested by funds: $9.54M → $4.85M (-$4.69M)
60% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$194K |
| 2 |
Renaissance Technologies
New York
|
+$77.8K |
| 3 |
VF
Virtu Financial
New York
|
+$61.4K |
| 4 |
EWA
EP Wealth Advisors
Torrance,
California
|
+$17.5K |
| 5 |
KPWS
Kestra Private Wealth Services
Austin,
Texas
|
+$9.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$353K |
| 2 |
WE
Wealth Effects
Boston,
Massachusetts
|
-$174K |
| 3 |
BlackRock
New York
|
-$104K |
| 4 |
Mercer Global Advisors
Denver,
Colorado
|
-$98.5K |
| 5 |
Two Sigma Investments
New York
|
-$87.7K |
LPCN Hedge Fund Activity: Q3 2022 in Review
46 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q3 2022, worth a combined $4.85M — down 49% from $9.54M a quarter earlier.
Fund positioning in LPCN was balanced in Q3 2022: 7 funds opened new positions, 7 closed out, 4 added to existing stakes and 10 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $194K. The largest seller was Marshall Wace, exiting entirely with an estimated $353K sold.
- 46 institutional investors held Lipocine (LPCN) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $4.85M of Lipocine stock for Q3 2022, down 49% quarter-over-quarter.
- 7 funds opened new Lipocine positions in Q3 2022 and 7 closed out, a net change of 0 holders.
- The largest Lipocine buyer in Q3 2022 was Citadel Advisors, an estimated $194K added.
- The largest Lipocine seller in Q3 2022 was Marshall Wace, an estimated $353K sold.
Based on aggregated 13F filings for Q3 2022.